Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714072 | 0.89 | NR1H4 (0.41) | SMN1; SMN2NR1H4KMT2AITKMEN1 | |
| SCHEMBL6715806 | 0.86 | NR1H4 (0.41) | SMN1; SMN2NR1H4KMT2AITKMEN1 | |
| SCHEMBL6714288 | 0.83 | HPGD (0.39) | SMN1; SMN2NR1H4KMT2AITKMEN1 | |
| SCHEMBL6716021 | 0.83 | TDP1 (0.46) | SMN1; SMN2NR1H4KMT2AITKMEN1 | |
| SCHEMBL6722821 | 0.78 | NPC1 (0.41) | NR1H4KMT2AITKMEN1ALDH1A1 | |
| SCHEMBL6719625 | 0.76 | OPRM1 (0.39) | NR1H4KMT2AITKMEN1NPC1 | |
| SCHEMBL6722876 | 0.71 | ALDH1A1 (0.39) | KMT2AITKMEN1ALDH1A1HPGD | |
| SCHEMBL7608888 | 0.68 | SMN1; SMN2 (0.47) | SMN1; SMN2NR1H4KMT2AMEN1ALDH1A1 | |
| SCHEMBL6726655 | 0.67 | IDH1 (0.38) | NR1H4ITK | |
| SCHEMBL6718318 | 0.67 | OPRM1 (0.41) | KMT2AMEN1ALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | SMN1; SMN2 1805/4885NR1H4 801/4885KMT2A 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.